It took decades to get to the GLP-1 breakthrough in obesity treatment. Now, the biopharma industry is clamoring over the field's next frontier: staving off the losses ...
Novo Nordisk A/S (NYSE:NVO) is advancing its research on a pioneering hybrid drug, CagriSema. This drug merges semaglutide ...
Welcome to the healthier, happier world of 2030. Heart attacks and strokes are down 20%. A drop in food consumption has left ...
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...
Cleveland Clinic expert discusses treatment options for obesity including weight loss drugs and bariatric surgery. Never miss ...
Zealand Pharma A/S said moderate doses of its experimental weight-loss drug helped patients pare pounds with less nausea than ...
The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose ...
PHILADELPHIA — Roux-en-Y gastric bypass (RYGB) produces maximal weight loss in patients with obesity compared with other ...
GoodRx has officially entered the weight loss drug market by offering an exclusive ... for chronic weight management in 2012. "Obesity medications are life-changing for millions of Americans ...
The full-year cost of care for U.S. patients with obesity ... which makes the GLP-1 weight-loss drug Zepbound, have reaped billions of dollars in profits since their new drugs hit the U.S ...
Oct. 25, 2024 — A new study has examined a large sample of privately insured patients with obesity and found ... Popular Diabetes and Weight-Loss Drug May Reduce Risk of Alzheimer's Disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback